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Background: We attempted to analyze the effects of an increase in the Child-Pugh (CP) score on the overall
survival of patients with unresectable hepatocellular carcinoma (HCC) after radiotherapy (RT).
Methods: From March 2006 to February 2012, 103 patients received RT using the TomoTherapy Hi-Art at Incheon
St. Mary’s Hospital and Seoul St. Mary’s Hospital. The dose per fraction was 1.8–5 Gy, and the total dose was
40–60 Gy (median, 50 Gy). We considered an increase of at least 2 points in the CP score within 3 months after RT
to be clinically important radiation-induced hepatic toxicity and analyzed the effects of an increased CP score on
overall survival.
Results: The median follow-up duration was 11.6 months (range, 3.5–85.3 months). The median survival time was
11.6 months. In multivariate analysis, planning target volume and an increase in the CP score after RT were found
to be a statistically significant factors (p = 0.010 and 0.015, respectively). In a comparison of cases with and without
an increase in the CP score, there was an 11.0-month difference in the median survival time (6.9 vs. 17.9 months),
and the relative risk of mortality was 1.8.
Conclusion: An increase of at least 2 points in the CP score within 3 months of RT completion is an important
on-treatment factor that affects overall survival. To minimize such increases, careful patient selection and a more
sophisticated radiation treatment plan are imperative.
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Radiotherapy (RT) for unresectable hepatocellular car-
cinoma (HCC) has been used in combination with other
local treatments such as transarterial chemoemboliza-
tion (TACE), percutaneous ethanol injection (PEI), and
radiofrequency ablation (RFA) [1-3]. Previously, RT was
not widely used because the whole liver could only tole-
rate low levels of radiation, and these low doses were in-
sufficient to effectively control tumors [4,5]. However,
recent studies have shown that partial volume irradiation
is both feasible and effective for tumor control with an
acceptable range of hepatic toxicity [6-8].* Correspondence: k41645@chol.com
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reproduction in any medium, provided the orRadiation-induced hepatic toxicity (RIHT) in HCC pa-
tients must be considered during RT. Currently, there is
no effective treatment for RIHT, which can induce liver
failure when not appropriately controlled. Thus, RIHT is
considered an important dose-limiting toxicity in HCC
patients who receive RT [9]. Therefore, studies have
attempted to identify predictive parameters to help re-
duce the incidence of RIHT, and the results have been
helpful in the establishment of radiation treatment plans
intended to reduce hepatic toxicity during RT [10-19].
The Child-Pugh (CP) score, which is calculated ac-
cording to the serum albumin and bilirubin levels, the
prothrombin time (PT), and the presence and degree
of encephalopathy or ascites, is a system for assessing
hepatic function. Therefore, an increase in the CP score
might reflect deterioration in hepatic function. Additionally,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B, non-C, PVTT
portal vein tumor thrombosis, AFP alpha-fetoprotein, AJCC American Joint
Committee on Cancer, TACE transcarterial chemoembolization,
RFA radiofrequency ablation, PEI percutaneous ethanol injection.
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administering additional treatments, disease progression
or liver failure, which can affect the patient’s prognosis,
can be developed [19-21].
In this study, we considered an increase of at least 2
points in the CP score within 3 months after the com-
pletion of RT to be an important RIHT. We attempted
to analyze the effects of such CP score increases on the
overall survival after RT and to discuss its importance.
Methods
Patients
The inclusion criteria for this study were as follows: 1)
unresectable HCC; 2) age >18 years; 3) a CP score of 5, 6,
or 7 within 1 month before RT; 4) an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1; 5)
an absence of distant metastases; 6) 2 or more laboratory
studies within 3 months after the completion of RT; 6) 1
or more radiological studies within 3 months after the
completion of RT; and 7) no disease progression within
3 months after the completion of RT.
A total of 103 patients were found to be eligible for this
study. All patients received RT using the TomoTherapy
Hi-Art system (TomoTherapy Inc., Madison, WI, USA) at
Incheon St. Mary’s Hospital and Seoul St. Mary’s Hospital
from March 2006 to February 2012. The patient data were
retrospectively reviewed following institutional review
board approval (IRB of Incheon St. Mary’s Hospital,
the Catholic University of Korea, Reference number:
OC12RISI0135).
Age, gender, ECOG performance status, American Joint
Committee on Cancer (AJCC) stage (7th edition), pretreat-
ment CP score, the absence or presence of hepatitis, liver
cirrhosis, or portal vein tumor thrombosis (PVTT),
the alpha-fetoprotein (AFP) level, and CP score within
3 months after the completion of RT were evaluated. Be-
fore RT, TACE was performed in 95 patients (median
number of procedures, 2; range, 1–11), PEI in 8 patients
(median number of procedures, 2; range, 1–3), RFA in 8
patients (median number of procedures, 2; range, 1–3),
and systemic chemotherapy in 14 patients. The patients’
characteristics are shown in Table 1.
Radiotherapy
For the simulations, patients were immobilized using
the BodyFix system (Medical Intelligence GmbH,
Schwabmunchen, Germany), in which the abdomen was
compressed under low pressure with foil. Next, a spiral
computed tomography (CT) scans were obtained using an
intravenous contrast agent and a 2.5-mm slice thickness
on either a SOMATOM (Siemens, Berlin, Germany) or a
LightSpeed RT16 (GE, Waukesha, WI, USA) CT scanner.
The gross tumor volume (GTV) was defined as the
tumor volume that was enhanced in the arterial phase ofthe CT scan and diluted in the delayed phase. The plan-
ning target volume (PTV) was generated by the addition
of 5–15 mm to the GTV in 71 of the 103 patients, which
facilitated an asymmetric margin expansion in order to
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intestine. In the remaining 32 patients, 4-dimensional
(4D) CT was performed to generate an internal target
volume in order to compensate for respiration-induced
liver movement; these 4D-CT scanners were installed in
March 2009 at Seoul St. Mary’s Hospital and in March
2011 at Incheon St. Mary’s Hospital. The organs at risk,
such as the total liver, non-target normal liver (NTNL),
stomach, duodenum, intestine, kidney, and spinal cord,
were also contoured for evaluation of the irradiated
dose. The NTNL volume was the total liver volume
minus the PTV.
The GTV was 122.8 ± 153.3 cm3, the PTV was 330.5 ±
275.1 cm3 and the normal liver volume was 1209.7 ±
426.9 cm3. The dose per fraction to the PTV was
1.8–5 Gy, and the total dose was 40–60 Gy (median,
50 Gy). The dose was prescribed to 95% of the PTV. The
treatment characteristics are shown in Table 2. The pre-
scribed dose varied according to the pretreatment CP class
and the PTV. When the PTV was small and the pretreat-
ment CP class was A, the prescribed dose was higher and
4–5 Gy per fraction was used. When the PTV was large
or the pretreatment CP class was B, the prescribed dose
was lower and 1.8–2.5 Gy per fraction was used. Additio-
nally, normal tissue constraints, which were used in our
institution at the time of the study, were applied (Table 3).
We intended to prescribe the PTV dose according to the
normal tissue constraints; however, these constraints were
not always satisfied in order to achieve adequate target
coverage and proper tumor dose. Treatment planning was
performed using the built-in software of the Tomo-
Therapy Planning Station, which was used with theTable 2 Treatment characteristics
Variables
GTV (cm3) 122.8 ± 153.3
PTV (cm3) 330.5 ± 275.1











1.8-2.5 Gy per fraction 41 (39.8%)
4–5 Gy per fraction 62 (60.2%)
Abbreviations: GTV gross tumor volume, PTV planning target volume,
BED biologically effective dose, EQD2 equivalent dose in 2-Gy fractions.TomoTherapy Hi-Art system. We evaluated the dose-
volume histogram (DVH) and dose distributions in a
slice-by-slice manner. We then approved the treatment
plan if tumor coverage was adequate and doses to the sur-
rounding normal tissue were within acceptable levels.
Megavoltage cone-beam CT was performed during each
treatment session before actual beam delivery. Patients’
set-up and position were corrected using automated
image registration, and anatomical accuracy was always
evaluated by a radiation oncologist.
Evaluation and analysis
We considered an increase of at least 2 points in the CP
score within 3 months after the completion of RT to be
a clinically important RIHT. The CP score, which is cal-
culated according to the serum bilirubin and albumin
levels, the PT, and the presence and degree of ascites or
encephalopathy, is used as a tool to assess hepatic func-
tion; thus, an increase in the CP score reflects deterior-
ation in the hepatic function [19,21].
The effects of clinical factors, including age, gender,
ECOG performance status, the presence or absence of
liver cirrhosis, hepatitis, PVTT, AFP level, pretreatment
CP class, and PTV, on overall survival were analyzed.
The effects of treatment factors, including the biolo-
gically effective dose (BED) and fraction size, on overall
survival were also analyzed. Furthermore, the effect of
an increase of at least 2 points in the CP score within
3 months after RT completion on overall survival after
RT was analyzed.
Statistical analyses
Overall survival was calculated from the date of RT to
the date of death or the last follow-up. The probability
of cumulative survival was calculated according to the
Kaplan-Meier method. Univariate and multivariate ana-
lyses were performed according to the Cox proportional
hazards models. Multivariate analysis was performed
according to the “enter” method. Significant variables in
univariate analysis were included in multivariate analysis.
The association between the clinical/tumor characteris-
tics and an increase in the CP score was analyzed using
the chi-square test and independent t-test. The statistical
analysis were performed using STATA 12.1 software
(StataCorp, College Station, TX, USA), and p values of
<0.05 were considered statistically significant.
Results
Overall survival and clinical factors that influence the
survival
The median follow-up duration was 11.6 months (range,
3.5–85.3 months). The median survival time was
11.6 months, and the 1-, 2-, and 3-year survival rates
were 48.5%, 23.4%, and 14.3%, respectively. In univariate
Table 3 Normal tissue constraints
1.8-2.0 Gy per fraction 2.5-3.0 Gy per fraction 4.0-5.0 Gy per fraction
Liver
TL-V30Gy < 60% TL-V20Gy < 60%
Mean dose < 31 Gy Mean dose < 30 Gy Mean dose < 22 Gy
Kidney V18Gy < 33% Mean dose < 16 Gy Mean dose < 13 Gy
Spinal cord D2cc < 45 Gy D2cc < 42 Gy D2cc < 33 Gy
Intestine D2cc < 50 Gy D2cc < 45 Gy D2cc < 35 Gy
Abbreviations: TL total liver, V30Gy volume of normal tissue that receives more than 30 Gy, D2ccmaximal dose to 2 cc of normal tissue.
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225 cm3, and an increase of at least 2 points in CP score
after RT were found to be statistically significant unfavo-
rable factors for overall survival (p = 0.038, 0.001, and
p <0.001, respectively). Gender, age, ECOG performance
status, AJCC stage, the level of AFP, the presence or ab-
sence of liver cirrhosis, hepatitis, PVTT, BED, and hypo-
fractionation were not found to be statistically significant

















Pretreatment CP class (B) 1.834
(1.033-3.257)
PTV (>225 cm3) 2.057
(1.355-3.125)
BED (>70 Gy) 0.839
(0.532-1.322)
Hypofractionation (≧4 Gy per fraction) 0.731
(0.479-1.116)
An increase in CP score after RT (≥2) 2.283
(1.494-3.484)
Abbreviations: HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative O
AFP alpha-fetoprotein, CP Child-Pugh, PTV planning target volume, BED biologically eand an increase of at least 2 points in the CP score after
RT were found to be statistically significant factors for
poor overall survival (p = 0.010 and 0.015, respectively).
The results of univariate and multivariate analyses are
summarized in Table 4.
The associations between the clinical/tumor characteris-
tics and an increase of at least 2 points in the CP score
are summarized in Table 5. PVTT (p = 0.027) and PTV
(p <0.001) were significantly associated with an increase inanalysis Multivariate analysis
















ncology Group performance status, PVTT portal vein tumor thrombosis,
ffective dose.
Table 5 Clinical and tumor characteristics assosiated with
an increase in CP score
Variables No toxicity Toxicity p value
Gender
Male 45 35 0.475
Female 11 12
Age
Median 60 57 0.142
Range 21-80 40-80
ECOG PS
0 18 20 0.275
1 38 27
Hepatitis
B 40 33 0.892
Others 16 14
Liver cirrhosis
No 19 13 0.493
Yes 37 34
PVTT
No 30 15 0.027
Yes 26 32
AFP
≤400 40 27 0.138
>400 16 20
Pretreatment CP class
A 52 39 0.120
B 4 8
PTV
≤225 cm3 42 18 <0.001
>225 cm3 14 29
BED
≤70 Gy 22 27 0.066
>70 Gy 34 20
Hypofractionation
<4 Gy per fraction 39 24 0.054
≥4 Gy per fraction 17 23
Abbreviations: HR hazard ratio, CI confidence interval, ECOG PS Eastern
Cooperative Oncology Group performance status, PVTT portal vein tumor
thrombosis, AFP alpha-fetoprotein, CP Child-Pugh, PTV planning target volume,
BED biologically effective dose.
Figure 1 Survival curves according to the presence or absence
of an increase in the CP score.
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(p = 0.054) were marginally significant factors that in-
fluenced an increase in the CP score.
Significance of an increase at least 2 points in CP score
after the completion of radiotherapy
An increase of at least 2 points in the CP score was
noted in 47 of the 103 patients (45.6%) after a mediantime of 1.7 months (range, 0.8–3.0 months) after RT
completion. Among these 47 patients, 5 patients (10.6%)
recovered from a CP score increase after a median time
of 2.73 months (range, 2.53–3.0 months) after RT com-
pletion. However, such recoveries were transient because
the CP scores increased again after a median time of
0.9 months (range, 0.13–1.13 months). In the absence of
an increase of at least 2 points in the CP score, the me-
dian survival time was 17.9 months, and the 1-, 2-, and
3-year survival rates were 66.1%, 34.7%, and 22.1%, re-
spectively. In the presence of an increase of at least 2
points in the CP score, the median survival time was
6.9 months, and the 1-, 2-, and 3-year survival rates were
27.7%, 10.2%, and 5.1%, respectively (Figure 1). In a
comparison between cases with increased CP scores and
those without increased CP scores, there was an 11.0-
month difference in the median survival time (6.9 vs.
17.9 months), and the relative risk of mortality was 1.8.
An increase of at least 2 points in the CP score was sig-
nificantly associated with the number of TACE procedures
after RT. TACE could be performed after RT in 64 of 103
patients (62.1%). In cases with no increase in the CP score,
the number of TACE procedures was 2.2 ± 2.8; however,
in cases with an increase in the CP score, the number of
TACE procedures was 1.1 ± 1.1, and this difference was
statistically significant (p = 0.01). When the analysis was
limited to patients who underwent TACE, the number of
TACE procedures in patients without an increased CP
score (3.7 ± 2.7) was significantly higher than that in
patients with an increased CP score (1.7 ± 0.9); this
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PEI were performed in 3 and 2 patients, respectively, after
RT, and none of these patients experienced an increase in
the CP score.
Discussion
RIHT is an important dose-limiting toxicity in HCC pa-
tients that must be considered during RT. Studies have
sought predictive factors such as dose-volumetric pa-
rameters based on DVH, and these parameters and their
values are being used to establish radiation treatment
plans. However, the definition of RIHT has varied in pre-
vious studies. Radiation-induced liver disease (RILD) is a
traditionally accepted concept of hepatic toxicity. Classic
RILD is a subacute hepatic toxicity that presents with
anicteric ascites, hepatomegaly, and elevated alkaline
phosphatase levels; it typically occurs between 4 and
8 weeks after the completion of RT [5,22]. Previously,
classic RILD was a serious problem that could occur in
response to radiation amounts of 30–35 Gy to the whole
liver; however, the incidence decreased after partial vol-
ume irradiation became more frequently used [13,14].
Kim et al. [10] considered an increase in hepatic en-
zymes above grade 2 to be RIHT according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
criteria. Dawson et al. [18] considered an increase in
hepatic enzymes above grade 3 to be RIHT, according to
the Radiation Therapy Oncology Group toxicity criteria.
Liang et al. [12], Lee et al. [15], and Cheng et al. [16]
considered hepatic enzyme levels higher than CTCAE
grade 3 to be RIHT and accordingly suggested predictive
parameters and their values.
The increase in hepatic enzyme level is temporary, and
thus, the levels recover within a few months [10]. In our
previous study, the increase in hepatic enzymes could
not be appropriately viewed as a dose-limiting toxicity
[14]. According to Furuse et al. [20], hypoalbuminemia,
hyperbilirubinemia, and ascites are important hepatic
events that can occur after RT for HCC treatment, and
these events can considerably affect patient survival. Al-
bumin, bilirubin, and ascites are the factors used to cal-
culate the CP score. Furthermore, an earlier study stated
that progression of the CP class is a useful dose-limiting
factor with which to predict the deterioration of hepatic
function [14]. An increase of at least 2 points in the CP
score was used to evaluate hepatic function deterioration
in patients who were treated with lamivudine by Liaw
et al. [21], and to find a predictive parameter in patients
who were treated with helical tomotherapy by Son et al.
[19]. For this reason, the CP score is appropriate for
evaluation of hepatic function, and an increase of at least
2 points in the CP score can be viewed as an important
factor with which to evaluate hepatic toxicity after RT.
Moreover, classic RILD and RIHT-related studies reportthe occurrence of this toxicity within 3–4 months
[10,11,13,17,22]. Therefore, it is reasonable to consider
an increase of at least 2 points in the CP score within
3 months to be RIHT.
However, an increased CP score could occur in re-
sponse to natural deterioration of the underlying liver
cirrhosis, tumor progression, and HCC treatment. To
minimize the effects of these events on the CP score, a
pretreatment CP score of 5–7, an ECOG performance
status of 0–1 and the absence of disease progression
within 3 months were used as inclusion criteria. Further-
more, the CP score was monitored for 3 months. Al-
though a shorter follow-up duration for the CP score
after the completion of RT could reduce the risk of in-
fluence of natural deterioration of liver cirrhosis, a
3-month follow-up duration was necessary in order to
evaluate RT-induced CP score increases according to
previous studies [10,11,13,17,19]. Moreover, we eva-
luated the laboratory results immediately prior to other
treatments to prevent errors caused by the transient ele-
vation of CP scores if additional treatments were per-
formed within the 3-month period after RT.
In our study, PTV of 225 cm3 and an increased CP
score were found to be significant factors that affected
overall survival in multivariate analysis. The pretreat-
ment CP class was a significant factor in univariate
analysis, but not in multivariate analysis (p = 0.353). Ac-
cording to Cheng et al. [16], the risk of RIHT was high
in cases of CP class B, and Liang et al. [12] reported that
the incidence of RIHT was higher in cases of CP class B
than in cases of CP class A. However, in a study by Yoon
et al. [23], the pretreatment CP class was determined to
be a factor that affects prognosis in univariate analysis,
but not in multivariate analysis. Larger tumor size is a
well-known poor prognostic factor in terms of tumor re-
sponsiveness or overall survival [6,23,24]. In our study,
an increase of at least 2 points in the CP score after the
completion of RT was found to be a significant factor in-
stead of the pretreatment CP class. In a comparison of
cases with and without an increase in CP score, there
was an 11.0-month difference in the median survival
time (6.9 vs. 17.9 months), and the relative risk of mor-
tality was 1.8. In a study of Liang et al. [13], there was
an 18-month difference in the median survival time,
which depend on the presence of RILD (4 vs. 22 months).
Thus, in that study, the difference in the median survival
time was larger than the difference in our study, and the
median survival time for the group with hepatic toxicity
was shorter (4 months in Liang et al. vs. 6.9 months in this
study). This might be because Liang et al.’s definition of
hepatic toxicity was different from ours. Nonetheless, our
results are similar in the sense that they show the impor-
tance of preventing such toxicity, because the overall sur-
vival is low in patients with hepatic toxicity.
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dures performed after RT differed according to whether
there was an increase in the CP score (3.7 ± 2.7 vs. 1.7 ±
0.9 times). This could be interpreted to mean that there
were fewer opportunities for additional treatments be-
cause of hepatic function deterioration in the group with
increased CP scores. Unresectable HCC is difficult to treat
completely with RT alone; therefore, treatments such as
TACE are repeatedly performed to obtain the maximum
effect. However, if it becomes difficult to administer such
procedures because of hepatic function deterioration, pa-
tient survival may be adversely affected because there are
few other opportunities to control tumor progression.
In conclusion, an increase of at least 2 points in the
CP score within 3 months of RT completion is an im-
portant on-treatment factor that affects overall survival.
To minimize such increases, careful patient selection
and a more sophisticated radiation treatment plan are
imperative.
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